Found: 5
Select item for more details and to access through your institution.
Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1363069
- By:
- Publication type:
- Article
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer.
- Published in:
- NPJ Precision Oncology, 2024, v. 8, n. 1, p. 1, doi. 10.1038/s41698-024-00704-9
- By:
- Publication type:
- Article
Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR -Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. N.PAG, doi. 10.3389/fonc.2020.607840
- By:
- Publication type:
- Article
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article